ClinicalTrials.gg
CompletedNCT00395018Updated May 31, 2012Results posted

Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection

A Phase 3 interventional study of entecavir in Hepatitis B, Chronic, sponsored by Bristol-Myers Squibb. Completed at 32 sites in 9 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2012-05-31.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
109
Allocation
Non-randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.

Enrollment
31st of 61
109 · median 109
Started
2007
with 6 others
Phase 3
13 of 64
none open now
Registered
7th of 64
by date
Lead sponsor
19 of 64
Bristol-Myers Squibb

Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 31st largest by enrollment of the 61 interventional ones that give a count, is one of 7 that started in 2007, is one of 13 in phase 3, and was the 7th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About entecavir

entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing entecavir in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

The purpose of this clinical research study is to learn if the study drug entecavir will prevent the recurrence of hepatitis B virus (HBV) in participants who receive an orthotopic liver transplant (OLT) due to HBV infection.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

Keywords

  • Chronic Hepatitis B Virus, Liver Transplant
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients receiving orthotopic liver transplant (OLT) due to end-stage liver disease because of chronic infection, with HBV-DNA \< 172 IU/mL (approximately \< 1000 copies/mL) prior to liver transplant
  • Must have detectable hepatitis B surface antigen (HBsAg) at screening and for at least 24 weeks prior to screening

Exclusion criteria

Exclusion Criteria:

  • Patients with hepatocellular carcinoma with evidence of extrahepatic spread, multiple tumors ≥ 6.5 cm in diameter or there is up to three nodules ≥ 4.5 cm in diameter and total tumor diameter is ≥ 8 cm
  • Co-infection with (HIV), cytomegalovirus (CMV), Epstein-Barr virus (EBV) or virus (HCV)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
109 participants (actual)

Study arms

  • Experimental
    entecavir

    Drug: entecavir

Interventions

  • Tablets, Oral, 1 mg, once daily, up to 72 weeks

    Also known as: Baraclude, BMS-200475

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) => 50 IU/mL by Polymerase Chain Reaction (PCR) at Week 72

    HBV DNA assessments were performed using the Roche COBAS® TaqMan High+Pure system (HPS) assay. HBV DNA =\> 50 IU/mL = approximately =\> 300 copies/mL.

    Time frame: At 72 weeks

  2. Number of Participants With HBV DNA by PCR >= 50 IU/mL Through Week 72

    HBV DNA assessments were performed using the Roche COBAS® TaqMan High+Pure system (HPS) assay. HBV DNA =\> 50 IU/mL = approximately =\> 300 copies/mL.

    Time frame: At baseline (day 1), week 12, 24, 36, 48, 60, and 72

Secondary outcomes

  1. Distribution of ALT Levels Through 72 Weeks: Overall

    ALT is an enzyme present in serum and various tissues of the body, associated commonly with the liver. Elevated levels of ALT often suggests existence of medical problems which includes viral hepatitis. Normal range varies from laboratory to laboratory. Values of 5-60 U/L is usually considered normal. ALT abnormality = \>1.25 x ULN (upper limit of normal).

    Time frame: On Day 1 (baseline) and at week 4, 12, 24, 36, 48, 60, 72

  2. Percentage of Participants With HBV DNA < 50 IU/mL (Approximately 300 Copies/mL) by PCR at the End of Post-dosing Follow-up

    HBV DNA assessments were to be performed using the Roche COBAS® TaqMan AmpliPrep assay. HBV DNA \< 50 IU/mL = approximately 300 copies/mL.

    Time frame: At 72 weeks + 24 weeks follow-up

  3. Percentage of Participants With HBeAg Loss at Week 72 (for HBeAg-positive Participants)

    HBeAg is a hepatitis B viral protein. HBeAg loss = HBeAg-negative at the specified analysis week.

    Time frame: At week 72

  4. Percentage of Participants With HBeAg Seroconversion at Week 72 (for HBeAg-positive Participants)

    HBeAg is a hepatitis B viral protein. HBeAg Seroconversion = HBeAg Loss and Presence of Hepatitis B e Antibody (HBeAb).

    Time frame: At week 72

  5. Percentage of Participants With HBsAg Loss at Week 72

    HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAg loss = HBsAg-negative at the specified analysis week.

    Time frame: At week 72

  6. Percentage of Participants With HBsAg Seroconversion at Week 72

    HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBs seroconversion is defined as HBsAg loss with positive HBsAb.

    Time frame: At week 72

  7. Percentage of Participants With HBsAg Recurrence At Week 72

    HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAg recurrence is defined as having detectable HBsAg among participants who have already experienced loss of HBsAg on-treatment. HBsAg recurrence = HBsAg-positive at the specified analysis week.

    Time frame: At week 72

  8. Total Bilirubin at Week 72

    Bilirubin measures are used to diagnose or monitor liver functioning or diseases that include hepatitis. Viral hepatitis is one of the condition in which bilirubin levels are elevated. Normal range varies from laboratory to laboratory. Bilirubin abnormality : =\> 1.1 x ULN mg/dL.

    Time frame: At week 72

  9. Prothrombin Time (PT) at Week 72

    Prothrombin, a liver protein, plays an important role in the extrinsic pathway of clotting. Increased prothrombin time indicates abnormal liver functioning. Normal prothrombin time varies from laboratory to laboratory. Generally, normal prothrombin time varies between 10 to 13.2 seconds. Abnormal PT: \> 1.01 x ULN.

    Time frame: At week 72

  10. Number of Participants With Liver Rejection Through Week 72

    Time frame: Through week 72

  11. Number of Participants With Re-transplantation Through Week 72

    Time frame: Through week 72

  12. Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations From Study Drug Due to AEs (On-treatment [OT] and Off-treatment Follow-up [OF])

    AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or an overdose. Toxicity grading by modified WHO grade system. Grade (GR) 2=moderate; GR3=severe; GR4=very severe. OT=from start of dosing to end of dosing+5 days; OF=from end of dosing+6 days to start of other anti-HBV therapy or end of follow-up.

    Time frame: OT:From start of dosing through Week 72 + 5 days; OF:End of OT through 24-weeks follow-up

  13. Number of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment Follow-up(OF): Hematology (All Grades)

    Criteria for hematology abnormalities were: Hemoglobin : \<11.0 g/dL; White Blood Cells : \<4000/mm\^3; Neutrophils : \<1500/mm\^3; Platelets : \< 99,000/mm\^3; International Normalized Ratio (INR) : increase \>= 0.5 from baseline.

    Time frame: OT:From start of dosing through Week 72 + 5 days; OF:End of OT through 24-weeks follow-up

  14. Number of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment (OF) Follow-up: Serum Chemistry (All Grades)

    Normal ranges are local lab data and vary according to the site. Criteria for laboratory abnormalities:ALT:\>1.25xULN;AST:\>1.25xULN;ALP:\>1.25xULN;Total Bilirubin:\>1.1xULN;Serum Lipase:\>1.10xULN;Creatinine:\>1.1xULN;Blood Urea Nitrogen:\>1.25xULN;Hyperglycemia:\>116mg/dL;Hypoglycemia:\<64mg/dL;Hyponatremia:\<132meq/L;Hypernatremia:\>148meq/L;Hypokalemia:\<3.4meq/L;hyperkalemia:\>5.6meq/L;Hypochloremia:\<93meq/L;Hyperchloremia:\>113meq/L;Albumin: Decrease \>= 1g/dL from baseline and \< 3 g/dL. HYPER=value\>ULN(upper limit of normal). HYPO=value\<LLN (lower limit of normal).

    Time frame: OT:From start of dosing through Week 72 + 5 days; OF:End of OT through 24-weeks follow-up

07

Results

Posted May 31, 2012

Participant flow

A total of 109 participants were enrolled at 27 investigative sites.

On-Treatment
Participant flow — On-Treatment
MilestoneEntecavir (ETV)
Started65
Discontinued prior to week 72 visit10
Discontinued at or after week 72 visit0
Completed55
Not completed10
Withdrew: Death4
Withdrew: Other reason2
Withdrew: Poor/non-compliance2
Withdrew: Subject no longer meets study criteria2
Off-Treatment Follow-up
Participant flow — Off-Treatment Follow-up
MilestoneEntecavir (ETV)
Started5
Completed1
Not completed4
Withdrew: Followup no longer required per protocol1
Withdrew: Lost to follow-up2
Withdrew: Poor/non-compliance1

Outcome measures

PrimaryPercentage of Participants With HBV Deoxyribonucleic Acid (DNA) => 50 IU/mL by Polymerase Chain Reaction (PCR) at Week 72

HBV DNA assessments were performed using the Roche COBAS® TaqMan High+Pure system (HPS) assay. HBV DNA =\> 50 IU/mL = approximately =\> 300 copies/mL.

Time frame:
At 72 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) => 50 IU/mL by Polymerase Chain Reaction (PCR) at Week 72
percentage of participantsEntecavir (ETV)
Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) => 50 IU/mL by Polymerase Chain Reaction (PCR) at Week 720 (0.0 to 5.9)
SecondaryDistribution of ALT Levels Through 72 Weeks: Overall

ALT is an enzyme present in serum and various tissues of the body, associated commonly with the liver. Elevated levels of ALT often suggests existence of medical problems which includes viral hepatitis. Normal range varies from laboratory to laboratory. Values of 5-60 U/L is usually considered normal. ALT abnormality = \>1.25 x ULN (upper limit of normal).

Time frame:
On Day 1 (baseline) and at week 4, 12, 24, 36, 48, 60, 72
Reported as:
Mean · U/L
Distribution of ALT Levels Through 72 Weeks: Overall
U/LEntecavir (ETV)
Baseline158.7 ± 36.20
Week 461.2 ± 10.12
Week 1228.4 ± 2.66
Week 24 (n=59)28.4 ± 3.37
Week 36 (n=58)41.2 ± 8.20
Week 48 (n=57)24.9 ± 1.91
Week 60 (n=53)30.6 ± 4.04
Week 72 (n=54)26.9 ± 2.81
SecondaryPercentage of Participants With HBV DNA < 50 IU/mL (Approximately 300 Copies/mL) by PCR at the End of Post-dosing Follow-up

HBV DNA assessments were to be performed using the Roche COBAS® TaqMan AmpliPrep assay. HBV DNA \< 50 IU/mL = approximately 300 copies/mL.

Time frame:
At 72 weeks + 24 weeks follow-up
Reported as:
Number · percentage of participants

No measurements were reported for this outcome.

SecondaryPercentage of Participants With HBeAg Loss at Week 72 (for HBeAg-positive Participants)

HBeAg is a hepatitis B viral protein. HBeAg loss = HBeAg-negative at the specified analysis week.

Time frame:
At week 72
Reported as:
Number · percentage of participants
Percentage of Participants With HBeAg Loss at Week 72 (for HBeAg-positive Participants)
percentage of participantsEntecavir (ETV)
Percentage of Participants With HBeAg Loss at Week 72 (for HBeAg-positive Participants)100 (59.0 to 100.0)
SecondaryPercentage of Participants With HBeAg Seroconversion at Week 72 (for HBeAg-positive Participants)

HBeAg is a hepatitis B viral protein. HBeAg Seroconversion = HBeAg Loss and Presence of Hepatitis B e Antibody (HBeAb).

Time frame:
At week 72
Reported as:
Number · percentage of participants
Percentage of Participants With HBeAg Seroconversion at Week 72 (for HBeAg-positive Participants)
percentage of participantsEntecavir (ETV)
Percentage of Participants With HBeAg Seroconversion at Week 72 (for HBeAg-positive Participants)0 (0.0 to 41.0)
SecondaryPercentage of Participants With HBsAg Loss at Week 72

HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAg loss = HBsAg-negative at the specified analysis week.

Time frame:
At week 72
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Loss at Week 72
percentage of participantsEntecavir (ETV)
Percentage of Participants With HBsAg Loss at Week 7296.7 (88.7 to 99.6)
SecondaryPercentage of Participants With HBsAg Seroconversion at Week 72

HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBs seroconversion is defined as HBsAg loss with positive HBsAb.

Time frame:
At week 72
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Seroconversion at Week 72
percentage of participantsEntecavir (ETV)
Percentage of Participants With HBsAg Seroconversion at Week 7280.3 (68.2 to 89.4)
SecondaryPercentage of Participants With HBsAg Recurrence At Week 72

HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAg recurrence is defined as having detectable HBsAg among participants who have already experienced loss of HBsAg on-treatment. HBsAg recurrence = HBsAg-positive at the specified analysis week.

Time frame:
At week 72
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Recurrence At Week 72
percentage of participantsEntecavir (ETV)
Percentage of Participants With HBsAg Recurrence At Week 723.3 (0.4 to 11.3)
SecondaryTotal Bilirubin at Week 72

Bilirubin measures are used to diagnose or monitor liver functioning or diseases that include hepatitis. Viral hepatitis is one of the condition in which bilirubin levels are elevated. Normal range varies from laboratory to laboratory. Bilirubin abnormality : =\> 1.1 x ULN mg/dL.

Time frame:
At week 72
Reported as:
Mean · mg/dL
Total Bilirubin at Week 72
mg/dLEntecavir (ETV)
Total Bilirubin at Week 720.79 ± 0.079
SecondaryProthrombin Time (PT) at Week 72

Prothrombin, a liver protein, plays an important role in the extrinsic pathway of clotting. Increased prothrombin time indicates abnormal liver functioning. Normal prothrombin time varies from laboratory to laboratory. Generally, normal prothrombin time varies between 10 to 13.2 seconds. Abnormal PT: \> 1.01 x ULN.

Time frame:
At week 72
Reported as:
Mean · seconds
Prothrombin Time (PT) at Week 72
secondsEntecavir (ETV)
Prothrombin Time (PT) at Week 7213.32 ± 0.305
SecondaryNumber of Participants With Liver Rejection Through Week 72
Time frame:
Through week 72
Reported as:
Number · participants
Number of Participants With Liver Rejection Through Week 72
participantsEntecavir (ETV)
Number of Participants With Liver Rejection Through Week 7218
SecondaryNumber of Participants With Re-transplantation Through Week 72
Time frame:
Through week 72
Reported as:
Number · participants
Number of Participants With Re-transplantation Through Week 72
participantsEntecavir (ETV)
Number of Participants With Re-transplantation Through Week 723
SecondaryParticipants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations From Study Drug Due to AEs (On-treatment [OT] and Off-treatment Follow-up [OF])

AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or an overdose. Toxicity grading by modified WHO grade system. Grade (GR) 2=moderate; GR3=severe; GR4=very severe. OT=from start of dosing to end of dosing+5 days; OF=from end of dosing+6 days to start of other anti-HBV therapy or end of follow-up.

Time frame:
OT:From start of dosing through Week 72 + 5 days; OF:End of OT through 24-weeks follow-up
Reported as:
Number · participants
Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations From Study Drug Due to AEs (On-treatment [OT] and Off-treatment Follow-up [OF])
participantsEntecavir (ETV)
Death-OT4
SAEs-OT36
SAEs-OF (n=5)0
Discontinuation due to AEs-OT0
Any AE-OT62
Any AE-OF (n=5)0
Related AEs-OT11
Grade 2 - 4 related AEs-OT8
Grade 3 - 4 AEs-OT30
SecondaryNumber of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment Follow-up(OF): Hematology (All Grades)

Criteria for hematology abnormalities were: Hemoglobin : \<11.0 g/dL; White Blood Cells : \<4000/mm\^3; Neutrophils : \<1500/mm\^3; Platelets : \< 99,000/mm\^3; International Normalized Ratio (INR) : increase \>= 0.5 from baseline.

Time frame:
OT:From start of dosing through Week 72 + 5 days; OF:End of OT through 24-weeks follow-up
Reported as:
Number · participants
Number of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment Follow-up(OF): Hematology (All Grades)
participantsEntecavir (ETV)
HEMOGLOBIN-OT56
HEMOGLOBIN-OF (n=5)1
WHITE BLOOD CELLS-OT50
WHITE BLOOD CELLS-OF (n=5)2
NEUTROPHILS (Includes absolute bands)-OT24
NEUTROPHILS (Includes absolute bands)-OF (n=5)1
PLATELETS-OT40
PLATELETS-OF (n=5)2
INR-OT (n=63)30
INR-OF (n=4)0
SecondaryNumber of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment (OF) Follow-up: Serum Chemistry (All Grades)

Normal ranges are local lab data and vary according to the site. Criteria for laboratory abnormalities:ALT:\>1.25xULN;AST:\>1.25xULN;ALP:\>1.25xULN;Total Bilirubin:\>1.1xULN;Serum Lipase:\>1.10xULN;Creatinine:\>1.1xULN;Blood Urea Nitrogen:\>1.25xULN;Hyperglycemia:\>116mg/dL;Hypoglycemia:\<64mg/dL;Hyponatremia:\<132meq/L;Hypernatremia:\>148meq/L;Hypokalemia:\<3.4meq/L;hyperkalemia:\>5.6meq/L;Hypochloremia:\<93meq/L;Hyperchloremia:\>113meq/L;Albumin: Decrease \>= 1g/dL from baseline and \< 3 g/dL. HYPER=value\>ULN(upper limit of normal). HYPO=value\<LLN (lower limit of normal).

Time frame:
OT:From start of dosing through Week 72 + 5 days; OF:End of OT through 24-weeks follow-up
Reported as:
Number · participants
Number of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment (OF) Follow-up: Serum Chemistry (All Grades)
participantsEntecavir (ETV)
ALANINE AMINOTRANSFERASE (ALT)-OT54
ALT-OF (n=4)0
ASPARTATE AMINOTRANSFERASE (AST)-OT56
AST-OF (n=4)0
ALKALINE PHOSPHATASE (ALP)-OT34
ALP-OF (n=4)1
ALBUMIN-OT (n=64)51
ALBUMIN-OF (n=3)0
TOTAL BILIRUBIN-OT57
TOTAL BILIRUBIN-OF (n=4)0
SERUM LIPASE-OT (n=64)37
SERUM LIPASE-OF (n=3)1
CREATININE-OT43
CREATININE-OF (n=4)0
BLOOD UREA NITROGEN-OT43
BLOOD UREA NITROGEN-OF (n=4)0
HYPERGLYCEMIA-OT (n=64)52
HYPERGLYCEMIA-OF (n=3)0
HYPOGLYCEMIA-OT (n=64)15
HYPOGLYCEMIA-OF (n=3)0
HYPERNATREMIA-OT7
HYPERNATREMIA-OF (n=4)0
HYPONATREMIA-OT14
HYPONATREMIA-OF (n=4)0
HYPERKALEMIA-OT15
HYPERKALEMIA-OF (n=4)0
HYPOKALEMIA-OT22
HYPOKALEMIA-OF (n=4)0
HYPERCHLOREMIA-OT11
HYPERCHLOREMIA-OF (n=4)0
HYPOCHLOREMIA-OT7
HYPOCHLOREMIA-OF (n=4)0
PrimaryNumber of Participants With HBV DNA by PCR >= 50 IU/mL Through Week 72

HBV DNA assessments were performed using the Roche COBAS® TaqMan High+Pure system (HPS) assay. HBV DNA =\> 50 IU/mL = approximately =\> 300 copies/mL.

Time frame:
At baseline (day 1), week 12, 24, 36, 48, 60, and 72
Reported as:
Number · participants
Number of Participants With HBV DNA by PCR >= 50 IU/mL Through Week 72
participantsEntecavir (ETV)
Baseline3 (1.0 to 13.7)
Week 12 (n = 54)0 (0.0 to 6.6)
Week 24 (n = 58)0 (0.0 to 6.2)
Week 36 (n = 10)0 (0.0 to 30.8)
Week 48 (n = 49)0 (0.0 to 7.3)
Week 60 (n = 48)0 (0.0 to 7.4)
Week 72 (n = 49)0 (0.0 to 7.3)

Adverse events

Collected over From start of dosing through Week 72 + 5 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Entecavir (ETV)—36/65 (55.4%)58/65 (89.2%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventEntecavir (ETV)
Renal failure acuteRenal and urinary disorders3/65
Hepatic artery thrombosisHepatobiliary disorders3/65
Aspartate aminotransferase increasedInvestigations2/65
DiarrhoeaGastrointestinal disorders2/65
Bile duct stenosisHepatobiliary disorders2/65
Alanine aminotransferase increasedInvestigations2/65
VomitingGastrointestinal disorders2/65
CholangitisHepatobiliary disorders2/65
PyrexiaGeneral disorders2/65
NauseaGastrointestinal disorders2/65
Most frequent other events
Showing 10 of 39
Most frequent other events
EventEntecavir (ETV)
HypertensionVascular disorders22/65
DiarrhoeaGastrointestinal disorders18/65
Abdominal painGastrointestinal disorders17/65
HyperglycaemiaMetabolism and nutrition disorders15/65
HeadacheNervous system disorders13/65
AscitesGastrointestinal disorders13/65
InsomniaPsychiatric disorders13/65
ConstipationGastrointestinal disorders12/65
Back painMusculoskeletal and connective tissue disorders12/65
Pleural effusionRespiratory, thoracic and mediastinal disorders11/65

Baseline characteristics

Age Continuous
Age Continuous(years)Entecavir (ETV)
Median51.0 (23 to 68)
Age, Customized
Age, Customized(participants)Entecavir (ETV)
21-64 years60
>=65 years5
Sex: Female, Male
Sex: Female, Male(Participants)Entecavir (ETV)
Female12
Male53
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Entecavir (ETV)
Asian24
Black/African American7
Native Hawaiian/Other Pacific Islander1
White25
Other8
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Entecavir (ETV)
Hispanic/Latino0
Not Hispanic/Latino14
Region of Enrollment
Region of Enrollment(participants)Entecavir (ETV)
Argentina2
Australia5
Brazil12
France12
Italy6
Korea, Republic of7
Spain3
Taiwan4
United States14
HBV DNA by PCR
HBV DNA by PCR(log10 IU/mL)Entecavir (ETV)
Median0.8 (0.8 to 3.7)
Hepatitis B Surface Antigen
Hepatitis B Surface Antigen(participants)Entecavir (ETV)
Positive61
Negative4

6 further baseline measures are reported on the registry.

08

Study locations

32 sites
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Tulane University Hospital & Clinic
    New Orleans, Louisiana 70112, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • University Of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • University Of Rochester Medical Center
    Rochester, New York 14642, United States
  • University Of Cincinnati Medical Center
    Cincinnati, Ohio 45267, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • Baylor College Of Medicine
    Houston, Texas 77030, United States
  • Local Institution
    Buenos Aires, C1181ACH, Argentina
  • Local Institution
    Woolloongabba, Queensland 4102, Australia
  • Local Institution
    Heidelberg, Victoria 3084, Australia
  • Local Institution
    Fortaleza, Ceara 60430, Brazil
  • Local Institution
    Porto Alegre, Rio Grande Do Sul 90035, Brazil
  • Local Institution
    Sao Paulo, 01246, Brazil
  • Local Institution
    Clichy Cedex, 92118, France
  • Local Institution
    Paris Cedex 12, 75571, France
  • Local Institution
    Villejuif, 94800, France
  • Local Institution
    Bologna, 40125, Italy
  • Local Institution
    Roma, 00133, Italy
  • Local Institution
    Roma, 00168, Italy
  • Local Institution
    Torrette Di Ancona, 60020, Italy
  • Local Institution
    Seoul, 110-744, Korea, Republic of
  • Local Institution
    Seoul, 120-752, Korea, Republic of
  • Local Institution
    Seoul, 135-710, Korea, Republic of
  • Local Institution
    Seoul, 138-736, Korea, Republic of
  • Local Institution
    Barcelona, 08035, Spain
  • Local Institution
    Barcelona, 08036, Spain
  • Local Institution
    Madrid, 280009, Spain
  • Local Institution
    Valencia, 46009, Spain
  • Local Institution
    Kaohsiung, 833, Taiwan
  • Local Institution
    Taipei, 112, Taiwan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2006
First posted
Nov 2, 2006
Start
Apr 2007
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Results first posted
May 31, 2012
Last update
May 31, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00395018
Responsible party
Sponsor
First posted
Nov 2, 2006
Start date
Apr 2007
Primary completion
Mar 2011
Completion
Mar 2011
Results posted
May 31, 2012
Last update
May 31, 2012

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Entecavir

Start the discussion